拨康视云今起招股：龚虹嘉基石认购2000万美元，专注眼科创新疗法

Core Viewpoint - The article discusses the IPO of BoKang Vision Pharmaceutical Co., Ltd., highlighting its market valuation, share issuance, and the intended use of raised funds for clinical development and commercialization of its core products [2][7]. IPO Details - BoKang Vision plans to issue 60,582,000 shares, with 6,058,500 shares available for public offering in Hong Kong and 54,523,500 shares for international offering [2]. - The IPO price is set at HKD 10.10 per share, leading to a market valuation of HKD 84.73 billion and a net fundraising amount of approximately HKD 5.22 billion [2]. Key Investors - The company has secured two cornerstone investors, raising a total of USD 22.8 million (approximately HKD 179 million), with notable participation from angel investor Gong Hongjia's FuCe Holdings and Ruikai Group [2][3]. Product Pipeline - BoKang Vision has two core products: CBT-001 for treating pterygium and CBT-009 for juvenile myopia, both of which are in advanced clinical stages [5][6]. - CBT-001 has initiated Phase 3 clinical trials in the US and China, aiming to be the first drug approved for pterygium treatment [5]. - CBT-009 completed Phase 1/2 trials and plans to submit a new drug application to the FDA in July 2024 [5]. Fund Utilization - The net proceeds from the IPO will primarily fund ongoing clinical research for CBT-001, regulatory submissions, and commercialization activities, as well as general corporate purposes [7].